iclusig - ponatinib hydrochloride tablet, film coated
(Ponatinib Hydrochloride)Takeda Pharmaceuticals America, Inc.
Usage: Iclusig is indicated for adult patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in combination with chemotherapy, and as monotherapy for specific cases. It is also approved for Chronic Myeloid Leukemia (CML) with resistance or intolerance to prior kinase inhibitors and T315I-positive CML.